Tvardi Regulatory Thursday, November 19, 2026 +0.20 Positive

Tvardi STAT3 inhibitor TTI-109 gains FDA pre-IND feedback

Tvardi Therapeutics received FDA feedback for next-gen STAT3 inhibitor TTI-109, aiming for a 2027 IND submission and distinguishing itself from JAK inhibitors with a selective profile.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed